Solventum: Q4 EPS Beats, Cash Flow Dips
Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory pressures.
Diversified healthcare company Solventum (NYSE:SOLV) reported fourth-quarter 2024 earnings on Thursday, Feb. 27, that topped analysts' consensus estimates. Adjusted EPS for the quarter came in at $1.41 against an anticipated $1.31 and revenue of $2.074 billion exceeded the expected $2.050 billion. Despite this, its adjusted free cash flow fell significantly to $92 million from $459 million year over year.
The overall quarterly performance was resilient against a backdrop of regulatory challenges and increased costs.
Source: Solventum. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year.
